Obstructive Sleep Apnea Clinical Trial
Official title:
Is Obstructive Sleep Apnoea a Risk Factor for Thoracic Aortic Aneurysm Expansion? A Prospective Cohort Study.
The objective of this prospective cohort study in patients with a known thoracic aortic aneurysm is to test the hypothesis that yearly aneurysm progression rate is higher in patients with obstructive sleep apnoea (OSA) compared to patients without OSA, and that the need for aortic operation or proven or presumed death from aortic rupture or dissection happens more often in patients with thoracic aortic aneurysm and OSA compared to patients without OSA.
Thoracic aortic aneurysm An aortic aneurysm is defined as a localised dilatation of the
aorta, which includes all three layers of the vessel, intima, media and adventitia. The
incidence of thoracic aortic aneurysm is estimated to be six to ten cases per 100,000 patient
years, most commonly occurring in the sixth and seventh decade of life. Thoracic aortic
aneurysms are two to four times more commonly found in males than in females. Sixty percent
of thoracic aortic aneurysms involve the ascending aorta, 40% the descending aorta, and 10%
involve the thoraco-abdominal aorta. The pathogenesis and natural history as well as the
therapy of thoracic aortic aneurysms differ for each of these segments.
Thoracic aneurysms of the ascending aorta are considered to result from cystic degeneration
of the media layer, a process associated with weakening of the aortic wall. Cystic medial
degeneration occurs with aging, but seems to be increased in some families and with arterial
hypertension. Other risk factors which have been suggested to be associated primarily with
thoracic aneurysm formation of the descending aorta are the same as those for atherosclerosis
(e.g. hypertension, smoking and hypercholesterolemia). Whether atherosclerosis itself is a
prerequisite for aortic aneurysm development is a matter of debate. A multifactorial,
non-atherosclerotic cause such as a defect in vascular structural proteins and breakdown of
extracellular matrix proteins in combination with increased mechanical stress has been
postulated as the most likely mechanism for thoracic aneurysm formation.
Transthoracic echocardiography, computed tomography or MR angiography are recommended for
serial re-evaluation of a thoracic aortic aneurysm.
Natural history data on thoracic aortic aneurysms is scarce; however, aneurysm diameter has
been shown to increase by 1 to 10 mm per year. The rate of expansion is related to the
diameter of the aneurysm with larger aneurysms expanding faster; the findings of an early
cohort study on the natural course of thoracic aortic aneurysms found a yearly expansion of
7.9mm in aneurysms >50mm, compared to 1.7mm in aneurysms ≤50mm.
In several series of patients, aneurysm rupture occurred in 32% to 68% of medically treated
patients. The most important identified risk factor for rupture seems to be the size of the
aneurysm; the yearly rate of dissection or rupture ranges from 2%, to 3%, to 7%, for thoracic
aortic aneurysms less than 50 mm, 50-59 mm, and ≥60 mm in diameter, respectively. Expansion
rate per year, male gender, hypertension, systemic steroid therapy and inflammation are other
factors associated with increased risk of aneurysm rupture.
Asymptomatic patients with a thoracic aortic aneurysm are usually managed medically with
blood pressure control using a beta blocker and serial evaluation of aneurysmal size
progression. Surgery is reserved for symptomatic patients, and for asymptomatic patients with
rapid aneurysm expansion (usually defined as >10mm per year), or an aneurysm diameter >50 to
60mm, depending on the affected aortic segment, body size and other clinical factors.
However, thoracic aneurysm repair is associated with high morbidity and mortality rates
between 3% and 12% in more recent retrospective series. In cases of emergency surgery for
thoraco-abdominal aneurysm the 30 day mortality has even been reported to be as high as 40%.
Therefore, any modifiable factors influencing the onset of a thoracic aneurysm and its
progressive expansion are of major interest, hopefully leading to new therapeutic strategies
to improve morbidity and mortality.
Obstructive sleep apnoea (OSA) is characterised by a repetitive collapse of the pharynx
during sleep, which results in apnoea or hypopnoea associated with oxygen desaturations and
arousals from sleep, often many hundred times per night. OSA, defined as apnoea-hypopnoea
index (AHI) of 5/h or higher, is a common but underdiagnosed sleep-related breathing disorder
affecting up to 25% of the middle-aged male population twenty years ago, that now is
substantially increased due to higher prevalence of obesity. It is estimated that 80-90% of
moderate to severe OSA are not diagnosed. The gold-standard diagnostic test for OSA is
in-laboratory polysomnography. Alternatively, OSA can be diagnosed with high sensitivity and
specificity - in subjects with high probability for OSA based on clinical symptoms - by
in-hospital respiratory polygraphy or portable monitor devices at home (cardiorespiratory
sleep study). The usual and most effective treatment for OSA is continuous positive airway
pressure (CPAP) therapy. A device delivers a continuous level of positive airway pressure
with fixed or auto-titrating pressure keeping airway patency and thereby preventing apnoeas
and hypopnoeas.
Preliminary data from observational and non-randomised studies indicate an association
between OSA and cardiovascular events. There is also evidence that severe symptomatic sleep
apnoea is associated with hypertension, stroke and myocardial infarction. The proposed
mechanisms underpinning the association between OSA and vascular dysfunction leading to
cardio- and cerebrovascular disease are increasingly large intrathoracic pressure changes
leading to mechanical stress on the heart and large artery walls, arousal-induced reflex
sympathetic activation with resultant repetitive blood pressure rises, sometimes to over
200mmHg, and intermittent hypoxia leading to increased oxidative stress and sympathetic
activity. The rises in blood pressure induce extensive shear stresses on blood vessel walls -
forces that are thought to cause vascular wall damage.
Recent findings from observational studies suggest a possible link between OSA, thoracic
aortic dilatation and aortic events in patients with Marfan's syndrome. Marfan's syndrome is
an inherited disorder of the connective tissue and aortic root dilatation with subsequent
rupture is the commonest life-threatening manifestation. In a cross-sectional study including
patients with Marfan's syndrome, the severity of OSA was positively correlated with the
diameter of the aortic root. In a recent prospective Marfan cohort study, the rate of aortic
events (defined as operation because of rapid progressive aortic dilatation, and death
because of aortic rupture) was compared between patients with and without OSA. Aortic-event
free survival was significantly shorter in patients with Marfan's syndrome and OSA compared
to patients without OSA, suggesting that OSA may be an important risk factor for aortic
events in Marfan's syndrome.
The underlying mechanisms through which OSA may promote aortic dilatation are not clear. OSA
has been shown to be associated with increased diurnal blood pressure as well as with large
and recurrent surges in blood pressure during apnoeic events, which is the main identified
risk factor for aortic dilatation and dissection. In addition, obstructive apnoeas are
associated with repeated inspiratory effort against the collapsed upper airway causing
recurrent large negative intrathoracic pressures (sometimes as low as -80 mmHg) and thereby
producing outward radial forces on intrathoracic structures including the aorta. This
hypothesis is supported by the findings of Peters et al. who reported increased aortic
diameters during obstructive apnoeas in an animal model. In healthy humans, experimentally
simulated obstructive apnoea/hypopnoea has also been shown to lead to an acute increase in
proximal aortic diameter and transmural pressures.
In a recently published cohort study of patients with abdominal aortic aneurysms, it was
shown that severe OSA may be associated with an accelerated expansion of abdominal aortic
aneurysms. Because there is only limited cross-sectional and inconclusive data on the
possible association between OSA and thoracic aortic aneurysm from non-Marfan study
populations a prospective large cohort study of patients with thoracic aortic aneurysms is
needed to investigate whether OSA is associated with faster progression of aortic dilatation,
and aortic events, in a high risk population. Should OSA appear to be a factor associated
with an increased risk for rapid aortic dilatation and aortic events, then a randomised
controlled trial in those with OSA would be appropriate, looking at the effect of continuous
positive airway pressure (the definitive treatment for OSA) on thoracic aortic dilatation.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05857384 -
Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs
|
Phase 1 | |
Recruiting |
NCT04547543 -
Follow-up of Apneic Patients by Visio-consultation
|
N/A | |
Recruiting |
NCT05371509 -
Novel Myofunctional Water Bottle to Reduce OSA and Snoring Study
|
N/A | |
Completed |
NCT02515357 -
Mediterranean Diet/Lifestyle Intervention in Obstructive Sleep Apnea
|
N/A | |
Completed |
NCT05582070 -
Effect on Sleep of Surgical Treatment of Severe Nasal Obstruction
|
N/A | |
Active, not recruiting |
NCT03189173 -
Combined Upper-airway and Breathing Control Therapies for Obstructive Sleep Apnea
|
Phase 2 | |
Completed |
NCT04084899 -
The Effect of CPAP on Lung Hyperinflation in Patients With OSA
|
||
Completed |
NCT03032029 -
Registry on the Treatment of Central and Complex Sleep-Disordered Breathing With Adaptive Servo-Ventilation
|
||
Recruiting |
NCT04028011 -
Clinical Evaluation of a Wearable Technology for the Diagnosis of Sleep Apnoea
|
||
Recruiting |
NCT06047353 -
Community Health Advocates for Motivating PAP Use in Our Neighborhoods.
|
N/A | |
Completed |
NCT05253963 -
Acute Effect of CPAP on Weight in Patients With Obstructive Sleep Apnea
|
N/A | |
Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
Recruiting |
NCT06150352 -
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
|
||
Completed |
NCT03589417 -
Postural Stability, Balance and Fall Risk in Patients With Obstructive Sleep Apnea
|
||
Recruiting |
NCT04335994 -
ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing
|
N/A | |
Withdrawn |
NCT04063436 -
Evaluation of a New Nasal Pillows Mask for the Treatment of Obstructive Sleep Apnea
|
N/A | |
Recruiting |
NCT05385302 -
Sociological Determinants of Positive Airway Pressure Adherence in OSA Patients
|
||
Recruiting |
NCT04572269 -
Metabolomics of Obstructive Sleep Apnea
|
||
Not yet recruiting |
NCT06467682 -
12-week Tele-exercise Program in Patients With OSA
|
N/A | |
Withdrawn |
NCT04011358 -
Retinal Vein Occlusion and Obstructive Sleep Apnea: A Case Control Study
|
N/A |